Navigation Links
Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,,and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology -

NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from a Phase II study - which will be published in the August 10, 2007 issue of the Journal of Clinical Oncology (JCO) and are now available as an Early Release Article at www.jco.org - demonstrate that ixabepilone, a Bristol-Myers Squibb Company investigational compound, has activity in patients with metastatic breast cancer whose tumors were resistant to three types of standard chemotherapy (anthracycline, taxane, and capecitabine). Currently, there are few proven treatment options available to patients with breast cancer whose disease has rapidly progressed through or whose disease is not responding to prior treatment with approved chemotherapies. This study was one of five Phase II ixabepilone studies published in this issue of JCO, including three additional studies in metastatic breast cancer and one in non-small cell lung cancer.

"Drug resistance is a major concern in treating patients with advanced disease," said Renzo Canetta, vice president, Oncology Global Clinical Research, Bristol-Myers Squibb. "The results of this study are important as they provide valuable information about this investigational compound and its potential in patients with advanced breast cancer that is no longer responding to any of the current U.S. approved chemotherapy treatments."

The 126 patients enrolled in the single-arm Phase II study (CA163081) had heavily pretreated, advanced metastatic breast cancer, which had progressed through three prior therapies (anthracycline, taxane and capecitabine). The primary endpoint was objective response rate, which is an assessment of the response to treatment as determined by the independent radiology facility (IRF). Secondary efficacy endpoints included duration of response, time to response, progres
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Mass.--(BUSINESS WIRE)--Jul 3, 2007 - EPIX,Pharmaceuticals, Inc. (NASDAQ:EPIX) ... executive officer of EPIX, is,scheduled to present at ... Tuesday, July 10, 2007 at 1:30 p.m.,(EDT) at ... The presentation will be webcast live and can ...
... DIEGO--(BUSINESS WIRE)--Jul 2, 2007 - Accelrys, Inc.,(NASDAQ:ACCL), the ... announced today that its CFO,Rick Russo, will present ... in New York on July 11, 2007 at,10:30 ... the Mandarin,Oriental Hotel July 10th-12th. In attendance will ...
Cached Medicine Technology:EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference 2Accelrys to Present to Investors at C.E. Unterberg Emerging Growth,Opportunities Conference 2
(Date:4/23/2014)... A novel compound that targets an important brain receptor ... addiction behaviors, including relapse behavior, a University at Buffalo ... evidence that this may be a novel lead compound ... exist., The UB research was published as an online ... In the study, the compound, RO5263397, severely blunted a ...
(Date:4/23/2014)... April 23, 2014Men whose testosterone falls below normal levels ... be overweight and have heart disease and type 2 ... testosterone-deficient men for further testing and possible treatment is ... Health , a peer-reviewed publication from Mary Ann Liebert, ... Journal of Men,s Health website at ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Ill. - In a country as wealthy as the United ... 12 seniors do not have access to adequate food due ... food insecure. , Recent research at the University of ... Survey (NHANES) revealed that the seniors who are dealing with ... , "In 2011, 8.35 percent of Americans over age 60 ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2
... be common in tropical countries along with the ... researchers in Houston, Texas whose study was published in ... available online. ,Staphylococcus aureus, or staph, ... in the nose of a quarter to a third ...
... the caregiver to a 12-year-old autistic boy who fell to ... being charged with the boy's// death. This despite the police ... his death. ,The boy's name has never been ... not say if they were reopening the case or what ...
... potent herbs, has now uncorked a new product: herbal wine. ... Thapa, a resident of tourist town Pokhara in western Nepal, ... ,For many families, alcohol is an integral part of ... local liquors thrive in Nepal's markets along with foreign beers, ...
... between overweight and infertility in women is well known, but ... the case of obese men.//, ,New research has ... that a man’s chances of getting infertile are enhanced by ... during the four years prior to participating in the study ...
... develop symptoms like chest pain or breathlessness almost 2 hours ... death victims were already at a risk as they had ... prevent sudden cardiac death can be made by learning to ... ,"Our study suggests that shifting the focus to educating ...
... often than biologists once thought. Cutting and rearrangement of the ... by// the human cells. ,The immune system of ... could also help researchers understand better how the immune system ... ,Depending on the specific type of protein required, an ...
Cached Medicine News:Health News:MRSA Linked with Rise in Bacterial Infections 2Health News:Nepal Uncorks 'Herbal Wine' 2Health News:Symptoms develop long before the 'Sudden' Cardiac Death 2Health News:'Mix and match' of proteins may have a significant role in immunity 2
Micro suture forceps....
30 Degree angle....
Operating microscope with motorized zoom and variable focus up to 405 mm....
Advanced operating microscope with zoom and variable focus up to 500 mm....
Medicine Products: